Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovation’s Sabril Gets Advisory Committee Nod; Risk Strategy To Address Vision Loss Needed

This article was originally published in The Pink Sheet Daily

Executive Summary

The recommendation is contingent upon development of a REMS to detect the risk of visual field defects.

You may also be interested in...



Sabril Benefits In Infantile Spasms Outweigh Risk Of Vision Loss, Advisory Committee Says

Ovation anti-epileptic gains second unanimous approval recommendation from FDA committee; limited clinical data on vision loss means post-market studies are likely.

Sabril Benefits In Infantile Spasms Outweigh Risk Of Vision Loss, Advisory Committee Says

Ovation anti-epileptic gains second unanimous approval recommendation from FDA committee; limited clinical data on vision loss means post-market studies are likely.

Ovation’s Sabril Visual Defect Is Topic Of FDA Meeting; Is End To Longest Review In Sight?

FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will evaluate vigabatrin for two epilepsy indications at a meeting rescheduled for Jan. 7-8.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel